PubMed HealthSearch

Biomedical subjects

U Gundert-Remy

Publications and source records attributed to U Gundert-Remy.

At least 55 records · Page 3Linked to original sources

[Sitosterol in familial hyperlipoproteinemia type II. A randomized double-blind cross-over study].

The effect of beta-sitosterol on the lipid and lipoprotein level was evaluated in a randomised double-blind cross-over trial in 24 patients with primary familial type II hyperlipoproteinaemia over a period of 16 weeks. All patients completed the trial, however 10 of them had to be excluded from the evaluation due to fluctuations of their body weight or unreliable drug intake. Sitosterol lowered the total cholesterol level by 12.5% (P less than 0.01) from 9.96 mmol/l (3.69 g/l) to 8.37 mmol/l (3.23 g/l). The LDL-cholesterol level was lowered by 19.5% (P less than 0.05). The sitosterol concentration in plasma was consistently lower than 0.3% of total cholesterol. No side effects or tachyphylaxis was observed in the course of the trial. A return to normal of an increased serum cholesterol level by a combination of a lipid lowering diet and sitosterol monotherapy was only achieved in one patient.

Adolescent

Serum digoxin levels in patients of a general practice in Germany.

Serum digoxin levels were determined in 33 outpatients of a general practice in the countryside, on three occasions at intervals of 8 weeks. All the patients were on long term digoxin treatment, about 2 years on average. About 14 days after the first and the second visits the results of the measurements were sent to the patients, with a comment about their reliability in taking treatment according to the serum digoxin level. At the first visit half of the serum digoxin level were lower than 0.5 ng/ml; the mean serum concentration was 0.52 ng/ml. There was no correlation between serum concentration and age, dose or creatinine level; but there was with replies to the question about regularity of drug intake. The mean serum level at the second and the third visits was 0.88 ng/ml and 0.89 ng/ml, respectively. A correlation was found between the dose and the serum digoxin level. From these results it seems that compliance by the patient plays a major role in producing steady state levels of drugs.

Aged

[Biological availability].

The term "bioavailability" is used to describe the actual percentage of a drug released from the dosage form, which reaches the receptor site in sufficient quantity to induce a biological effect. In this connection there are many problems arising in conjunction with the formulation of the preparation, as well as through the interaction of physiological and pathological factors. Prerequisite to the bioavailability of an orally administered preparation is, firstly, the quick disintegration of the dosage form, and secondly, the release and dissolution of the active substance. No in vitro methods for the examination of these factors have as yet been evolved which would allow a reliable prediction of bioavailability in man. Animal experiments only permit limited prognoses, since numerous influential factors, such as absorption from the intestine, metabolism and metabolic rates, influence of physical and mental stress, etc., strongly dependent upon the species. Bioavailability is determined using pharmacokinetical techniques on the area affected by the dose-response curve, or a combination of these methods.

Administration, Oral

Biliary and urinary excretion of sulfated, glucuronidated and tetrahydroxylated bile acids in cirrhotic patients.

In patients with hepatobiliary diseases, considerable amounts of sulfated and glucuronidated bile acids are excreted in urine. Information on the biliary excretion of these compounds is lacking. We used an intestinal perfusion method to determine the biliary excretion of sulfated and glucuronidated bile acids in eight patients with alcoholic cirrhosis and moderately severe cholestasis and compared results with urinary excretion rates. In bile, the patients excreted 508.7 mumoles per hr (mean) nonsulfated, nonglucuronidated bile acids, 8.1 mumoles per hr sulfated bile acids and 4.0 mumoles per hr glucuronidated bile acids. In urine, these patients excreted 0.27 mumoles per hr nonsulfated, nonglucuronidated bile acids, 0.88 mumoles per hr sulfated bile acids and 0.02 mumoles per hr glucuronidated bile acids. Sulfates and glucuronides of mono-, di- and trihydroxy bile acids were detected in urine and bile. In urine, tetrahydroxy bile acids were only excreted as nonsulfated and nonglucuronidated forms. The bile:urine excretion ratio of sulfated bile acids was 9:1 and of glucuronidated bile acids was 226:1. In alcoholic cirrhosis with cholestasis, biliary excretion is an important excretory route of sulfated and glucuronidated bile acids.

Adult